It is possible that blocking the IL-8 function with antagonists to reduce the intermittent hypoxia-induced chemotactic migration of monocytes, an early inflammatory process of atherosclerosis, could be one potential strategy to reduce the progression of atherosclerosis in patients with OSA. This evidence concerns the gene CXCL8 and atherosclerosis.